Nuvation Bio Inc. (NUVB) FY2025 10-K Annual Report
Nuvation Bio Inc. (NUVB) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Nuvation Bio Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Global oncology focused on developing novel small molecule therapies for difficult-to-treat cancers, leveraging medicinal chemistry and clinical data
- • New emphasis: U.S. commercial launch of IBTROZI (taletrectinib) for ROS1+ NSCLC approved June 2025, plus new Eisai partnership for European and other territories in 2026
- • Strategic shift: Expansion into global commercialization via partnerships in China, Japan, Europe, and additional territories, extending reach beyond prior regional focus
- • Quantitative highlight: 71 U.S. commercial field team members for IBTROZI launch, with nearly 300 patients enrolled in pivotal Phase 2 global clinical trial program
- • Noteworthy: Median duration of response for IBTROZI matured to 50 months by August 2025, supporting its potential as new standard of care in ROS1+ NSCLC
Management Discussion & Analysis
- • Revenue and profitability data not disclosed in MD&A section
- • No segment performance details provided
- • No cash flow, buybacks, dividends, or capex information given
- • Forward-looking statements caution on risks causing actual results to differ materially
- • No specific management outlook or financial guidance included
Risk Factors
- • Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment
- • Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments
- • Operational risk: High R&D expenses increased by $16M in 2025 driven by clinical trial costs and headcount growth, with continued need for funding
- • Competitive risk: Phase 3 TRUST-III study compares taletrectinib to crizotinib in China, a key competitor in ROS1+ NSCLC market
- • Financial risk: $250M non-dilutive financing includes $150M synthetic royalty financing with tiered royalties up to 2.0x investment, plus $100M senior secured loan at SOFR+6% interest
Nuvation Bio Inc. FY2025 Key Financial MetricsXBRL
Revenue
$63M
▲ +699.0% YoY
Net Income
-$205M
▲ +64.0% YoY
Operating Margin
-338.7%
▲ +718861bp YoY
Net Margin
-325.3%
▲ +688845bp YoY
ROE
-66.9%
▲ +5552bp YoY
Total Assets
$595M
▲ +10.0% YoY
EPS (Diluted)
$-0.60
▲ +71.6% YoY
Operating Cash Flow
-$173M
▼ -33.0% YoY
Source: XBRL data from Nuvation Bio Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Nuvation Bio Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.